Epstein-barr virus - Associated posttransplantation lymphoproliferative disorder with tacrolimus metabolism deterioration in infants after living-donor liver transplantation

Transplantation

Volumn 99, Issue 1, 2015, Pages 114-119

  Fukushima, Daizo ^a   Sato, Kazushige ^a   Kawagishi, Naoki ^a   Ohuchi, Noriaki ^a   Satomi, Susumu ^a  

^a TOHOKU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

STEROID; TACROLIMUS; VIRUS DNA; BIOLOGICAL MARKER; IMMUNOSUPPRESSIVE AGENT;

ACUTE GRAFT REJECTION; ARTICLE; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG DOSE REDUCTION; DRUG METABOLISM; DRUG WITHDRAWAL; EPSTEIN BARR VIRUS; EPSTEIN BARR VIRUS ASSOCIATED POSTTRANSPLANT LYMPHOPROLIFERATIVE DISEASE; EPSTEIN BARR VIRUS INFECTION; FEMALE; GRAFT RECIPIENT; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFANT; LIVER GRAFT REJECTION; LIVER TRANSPLANTATION; LIVING DONOR; MALE; MINIMUM PLASMA CONCENTRATION; POSTTRANSPLANT LYMPHOPROLIFERATIVE DISEASE; PRESCHOOL CHILD; RETROSPECTIVE STUDY; VIRUS LOAD; VIRUS TRANSMISSION; AGE; BLOOD; DRUG MONITORING; EPSTEIN-BARR VIRUS INFECTIONS; GENETICS; LYMPHOPROLIFERATIVE DISORDERS; PREDICTIVE VALUE; RISK FACTOR; VIROLOGY;

AGE FACTORS; BIOLOGICAL MARKERS; DNA, VIRAL; DRUG MONITORING; EPSTEIN-BARR VIRUS INFECTIONS; FEMALE; HERPESVIRUS 4, HUMAN; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INFANT; LIVER TRANSPLANTATION; LIVING DONORS; LYMPHOPROLIFERATIVE DISORDERS; MALE; PREDICTIVE VALUE OF TESTS; RETROSPECTIVE STUDIES; RISK FACTORS; TACROLIMUS; VIRAL LOAD;

EID: 84920261475     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0000000000000255     Document Type: Article

References (22)

1. Praghakaran K, Wise B, Chen A, et al. Rational management of posttransplant lymphoproliferative disorder in pediatric recipients. J Pediatr Surg 1999;34:112.
2. Taylor AL, Marcus R, Bradley JA. Post-transplant lymphoproliferative disorders (PTLD) after solid organ transplantation. Crit Rev Oncol Hematol 2005;56:155.
3. Choquet S, Leblond V, Herbrecht R, et al. Efficacy and safety of rituximab in B-cell post-transplantation lymphoproliferative disorders: results of a prospective multicenter phase 2 study. Blood 2006;107:3053.
4. Jain AB, Marcos A, Pokharna R, et al. Rituximab (chimeric anti-CD20 antibody) for posttransplant lymphoproliferative disorder after solid organ transplantation in adults: long-term experience from a single center. Transplantation 2005;80:1692.
5. Oertel SH, Verschuuren E, Reinke P, et al. Effect of anti-CD 20 antibody rituximab in patients with post-transplant lymphoproliferative disorder (PTLD). Am J Transplant 2005;5:2901.
6. Molmenti EP, Nagata DE, Roden JS, et al. Post-transplant lymphoproliferative syndrome in the pediatric liver transplant population. Am J Transplant 2001;1:356.
7. Stieber AO, Boillot O, Scotti-Foglieni C, et al. The surgical implications of the posttransplant lymphoproliferative disorders. Transplant Proc 1991;23(1 pt 2): 1477.
8. Campo E, Swerdlow SH, Harris NL, et al. The 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applications. Blood 2011;117:5019.
9. Guthery SL, Heubi JE, Bucuvalas JC, et al. Determination of risk factors for Epstein-Barr virus-associated posttransplant lymphoproliferative disorder in pediatric liver transplant recipients using objective case ascertainment. Transplantation 2003;75:987.
10. Parker A, Bowles K, Bradley JA, et al. Diagnosis of post-transplant lymphoproliferative disorder in solid organ transplant recipients - BCSH and BTS guidelines. Br J Haematol 2010;149:675.
11. Sokal EM, Antunes H, Beguin C, et al. Early signs and risk factors for the increased incidence of Epstein-Barr virus-related posttransplant lymphoproliferative diseases in pediatric liver transplant recipients treated with tacrolimus. Transplantation 1997;64:1438.
12. Vegso G, Hajdu M, Sebestyen A. Lymphoproliferative disorders after solid organ transplantation-classification, incidence, risk factors, early detection and treatment options. Pathol Oncol Res 2011;17:443.
13. Tanner JE, Alfieri C. The Epstein-Barr virus and post-transplant lympho-proliferative disease: interplay of immunosuppression, EBV, and the immune system in disease pathogenesis. Transpl Infect Dis 2001;3:60.
14. Jain A, Nalesnik M, Reyes J, et al. Posttransplant lymphoproliferative disorders in liver transplantation: a 20-year experience. Ann Surg 2002;236:429.
15. Berengue JI, Lopez-Espinosa JA, Ortega-Lopez J, et al. Two-to threefold increase in blood tacrolimus (FK506) levels during diarrhea in livertransplanted children. Clin Transplant 2003;17:249.
16. HochleitnerBW, Bosmuller C, Nehoda H, et al. Increased tacrolimus levels during diarrhea. Transpl Int 2001;14:230.
17. Lemahieu W, Maes B, Verbeke K, et al. Cytochrome P450 3A4 and P-glycoprotein activity and assimilation of tacrolimus in transplant patients with persistent diarrhea. Am J Transplant 2005;5:1383.
18. Sato K, Amada N, Sato T, et al. Severe elevations of FK506 blood concentration due to diarrhea in renal transplant recipients. Clin Transplant 2004;18:585.
19. Webster A, Woodroffe RC, Taylor RS, et al. Tacrolimus versus cyclosporin as primary immunosuppression for kidney transplant recipients. Cochrane Database Syst Rev 2005; CD003961.
20. Drebber U, Kasper HU, Krupacz J, et al. The role of Epstein-Barr virus in acute and chronic hepatitis. J Hepatol 2006;44:879.
21. Narkewicz MR, Dell Olio D, Karpen SJ, et al. Pattern of diagnostic evaluation for the causes of pediatric acute liver failure: an opportunity for quality improvement. J Pediatr 2009;155:801.
22. Grenier FC, Luczkiw J, Bergmann M, et al. A whole blood FK 506 assay for the IMx analyzer. Transplant Proc 1991;23:2748.